Determination of COL1A1-PDGFB breakpoints by next-generation sequencing in the molecular diagnosis of dermatofibrosarcoma protuberans.


Journal

Experimental and molecular pathology
ISSN: 1096-0945
Titre abrégé: Exp Mol Pathol
Pays: Netherlands
ID NLM: 0370711

Informations de publication

Date de publication:
10 2021
Historique:
received: 29 03 2021
revised: 31 07 2021
accepted: 03 08 2021
pubmed: 10 8 2021
medline: 24 12 2021
entrez: 9 8 2021
Statut: ppublish

Résumé

In most cases, dermatofibrosarcoma protuberans (DFSP) is characterized by the chromosomal translocation t (17; 22) (q22; q13) that leads to a fusion of collagen type 1 alpha 1 (COL1A1) and platelet-derived growth factor beta chain (PDGFB). Recently, next-generation sequencing (NGS) has been reported to detect fusion transcripts in some malignancies. Therefore, the present study aimed to evaluate the utility of the targeted NGS in detecting the COL1A1-PDGFB fusion in patients with DFSP. We designed a targeted DNA capture panel to tile along the fusion regions, including exon, intron, and untranslated regions of the COL1A1 and PDGFB. A cohort of 18 DNA samples extracted from formalin-fixed, paraffin-embedded tissues was used to evaluate the targeted NGS. The results were compared with that of fluorescence in situ hybridization (FISH). The COL1A1-PDGFB fusion was identified in 13 of 18 cases (72.2%) by targeted NGS assay. PDGFB breakpoints were constantly found in exon 2, while breakpoints in COL1A1 varied from exon 15 to 46. Of these 18 cases assayed by FISH, 12 (66.7%) exhibited COL1A1-PDGFB fusion signals. One case (P9), which was FISH-negative, was demonstrated with the fusion by targeted NGS and validated by PCR and Sanger sequencing. The targeted NGS results showed a high concordance with the results of the FISH assay (94.4%). Our study reported a targeted NGS assay for detecting the breakpoints of the COL1A1-PDGFB fusion gene, which can be implemented in diagnosing patients with DFSP.

Identifiants

pubmed: 34371012
pii: S0014-4800(21)00071-X
doi: 10.1016/j.yexmp.2021.104672
pii:
doi:

Substances chimiques

COL1A1 protein, human 0
Collagen Type I, alpha 1 Chain 0
Oncogene Proteins, Fusion 0
Proto-Oncogene Proteins c-sis 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104672

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Ruizheng Zhu (R)

Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.

Jianna Yan (J)

Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.

Benshang Li (B)

Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Department of Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Fei Tan (F)

Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.

Wannian Yan (W)

Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.

Juan Shen (J)

Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.

Lingzhi Fan (L)

Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.

Lixia Ding (L)

Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Department of Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Yuchong Chen (Y)

Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.

Yichen Tang (Y)

Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.

Yeqiang Liu (Y)

Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: 1500156@tongji.edu.cn.

Yun Bai (Y)

Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: baiyun@chgc.sh.cn.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH